<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1228">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090893</url>
  </required_header>
  <id_info>
    <org_study_id>15-001713</org_study_id>
    <nct_id>NCT03090893</nct_id>
  </id_info>
  <brief_title>Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients</brief_title>
  <official_title>A Pilot Study, Prospective, Non-Randomized, Non-Blinded, Single-Center Study Evaluating the Response of Continuous Recombinant Antithrombin (ATryn) Infusion in Postcardiotomy ECMO Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>rEVO Biologics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study will be to prospectively evaluate the response of a continuous
      infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and
      maintain the AT activity within a specified range in adult patients that require
      extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and
      cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time within the serum AT level target range of 80-100%</measure>
    <time_frame>72 hour infusion period</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Antithrombin Deficiency Type 2</condition>
  <arm_group>
    <arm_group_label>Infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATryn continuous infusion</intervention_name>
    <description>replenish serum thrombin levels</description>
    <arm_group_label>Infusion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed cardiac surgery with Cardiopulmonary Bypass and subsequently placed on
             venoarterial (VA) Extracorporeal Membrane Oxygenation (ECMO) support at any point
             during the ongoing hospitalization

          -  Serum Antithrombin &lt; 60%.

        Exclusion Criteria:

          -  Heart transplantation during ongoing hospitalization

          -  Excessive bleeding (300 ml/hr of chest tube drainage for 2 consecutive hours)

          -  Weight &lt; 40 kg

          -  Allergy to goat products

          -  Anticoagulation with a direct thrombin inhibitor

          -  Religious exception to blood products

          -  Hypothermia (&lt; 34°C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William C. Oliver, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Lee, RN</last_name>
    <phone>507-255-5851</phone>
    <email>Lee.Eric@mayo.edu</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>March 21, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>William C. Oliver</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antithrombin III Deficiency</mesh_term>
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>will not share individual patient data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
